HB3454 Summary

• Requires prescribers to offer naloxone hydrochloride or FDA-approved opioid reversal medication when patients meet certain overdose risk criteria, effective January 1, 2022.

• Mandates naloxone offers when opioid prescription dosage reaches 90 or more morphine milligram equivalents per day, or when opioids are prescribed concurrently with benzodiazepines.

• Requires naloxone offers for patients with history of overdose, substance use disorder, or risk of returning to high-dose opioid use after loss of tolerance.

• Requires prescribers to provide education on overdose prevention and naloxone use to patients and, for minors, to parents or guardians.

• Exempts prescribers treating inmates or youth under Department of Corrections or Department of Juvenile Justice jurisdiction; non-compliance subject to administrative sanctions by licensing boards.